✦ LIBER ✦

Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma

✍ Scribed by Masataka Ohta; David Berd; Masayoshi Shimizu; Hirokazu Nagai; Maria-Grazia Cotticelli; Michael Mastrangelo; Jerry A. Shields; Carol L. Shields; Carlo M. Croce; Kay Huebner

Publisher: John Wiley and Sons
Year: 1996
Tongue: French
Weight: 750 KB
Volume: 65
Category: Article
ISSN: 0020-7136
DOI: 10.1002/(sici)1097-0215(19960315)65:6<762::aid-ijc9>3.0.co;2-x

No coin nor oath required. For personal study only.

✦ Synopsis

The cyclin-dependent kinase-4 inhibitor gene CDKN2, localized at chromosome region 9 ~2 1 , has been shown to be a familial melanoma gene, though we found that mutations of it are rare in uncultured sporadic melanomas. To determine whether the region of allelic loss at 9p2 I frequently observed in sporadic melanomas includes the CDKN2 locus, new polymorphic microsatellite probes were isolated from the genomic segments surrounding the CDKN2 gene and used for the study of loss of heterozygosity (LOH) in melanoma. The LOH study of matched uncultured tumor-constitutional DNA pairs from 66 metastatic cutaneous and I 9 primary uveal melanomas showed that 63% and 32% of the respective tumors suffered allelic loss in the 9p2 I region. Two regions of common losses which did not include the CDKN2 locus were observed in a region of common loss near the 095157 locus, telomeric to the CDKN2 locus, deletions were observed in 5 I Yo of informative cases; in the other region of common loss, near the D9S171 locus, centromeric to the CDKN2 locus, deletions were observed in 47% of informative cases. At the D9S974 locus, located within 20 kb of the CDKN2 gene, deletions were observed in 43% of informative cases. Homozygous deletions of the CDKN2 locus were observed in 8 cases of cutaneous melanoma and 2 cases of uveal melanoma; mutations in CDKN2 exon 2 were found in 2 of the 46 cases with allelic deletion in 9p2 I. Our results support the following conclusions: (i) somatic mutation of the CDKNZ gene is rare in sporadic melanomas with allelic loss at 9p2I; (ii) homozygous loss is more frequent than mutation of the CDKN2 gene in sporadic melanomas; (iii) at 9p2 I-p23 genes other than CDKN2 may be involved in the development of sporadic melanomas.

📜 SIMILAR VOLUMES

Deletion mapping of the tumor suppressor

Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21

✍ Florence Lerebours; Sylviane Olschwang; Bénédicte Thuille; Annette Schmitz; Pier 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 2 views

Several somatic genetic alterations have been described in colorectal carcinoma (CRC). Recurrent chromosomal deletions have suggested the presence of tumor suppressor genes (TSG) specifically involved in colorectal carcinogenesis. For one of them, two non-overlapping regions have been proposed on th

Affected members of melanoma-prone famil

Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF

✍ Ling Liu; Alisa M. Goldstein; Margaret A. Tucker; Herbert Brill; Nelleke A. Grui 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Mutations in the gene encoding the cell cycle inhibitor CDKN2A have been identified in some melanoma kindreds linked to 9p21. However, many such families show no evidence of mutations in the coding regions of CDKN2A. In this study, we examined whether two other potential tumor suppressors, CDKN2B an

Frequent allele loss on 9p21–22 defines

Frequent allele loss on 9p21–22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer

✍ Han-Xiang An; Dieter Niederacher; Frauke Picard; Claudia van Roeyen; Hans Georg 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

Genetic studies of chromosome arm 9p have indicated the presence of one or more tumor suppressor genes involved in genetic susceptibility to various types of human cancers. To define the extent of the specific deletion of 9p2 1-22 in human breast cancer, we have analyzed loss of heterozygosity and h

Detailed deletion mapping of chromosome

Detailed deletion mapping of chromosome arm 3p in breast cancers: A 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors

✍ Satoshi Matsumoto; Fujio Kasumi; Goi Sakamoto; Masahiko Onda; Yusuke Nakamura; M 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

Loss of heterozygosity (LOH) on 3p is frequent in human renal cell carcinomas, lung cancers, and breast cancers. To define the region(s) on 3p that harbor presumptive tumor suppressor gene(s) for breast cancer, we examined 196 primary breast tumors for their patterns of LOH at 22 microsatellite mark

Mapping of the gene for interferon-induc

Mapping of the gene for interferon-inducible dsRNA-dependent protein kinase to chromosome region 2p21-22: A site of rearrangements in myeloproliferative disorders

✍ Samir M. Hanash; Laura Beretta; Christine L. Barcroft; Susan Sheldon; Thomas W. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB 👁 1 views

Recent evidence suggests that the human interferon-inducible double-stranded RNA-dependent protein kinase may function as a tumor suppressor. Here we describe the mapping of the gene for this kinase to chromosome region 2p2 1-22 by fluorescence in situ hybridization. A combined analysis of cytogenet

High-resolution deletion mapping of chro

High-resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumors reveals a common chromosomal disruption within the Smith-Magenis region, an unstable region in chromosome band 17p11.2

✍ Wolfram G. Scheurlen; Peter Seranski; Antonia Mincheva; Joachim Kühl; Niels Söre 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 3 views

Loss of heterozygosity (LOH) on chromosome arm 17p is the most common genetic aberration in childhood primitive neuroectodermal tumors (PNETs). To determine the frequency and extent of 17p deletions, 29 loci on 17p were investigated in 24 tumors by using restriction fragment length polymorphism (RFL